Compare Stocks: CLRB, RFL, FBIO, and ALDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.58 +1.9%	$1.80	$1.07 ▼ $6.18	$93.51M	1.21	897,182 shs	982,193 shs
CLRB Cellectar Biosciences	$2.66 +2.7%	$2.58	$2.20 ▼ $6.52	$24.48M	0.55	40,838 shs	56,234 shs
FBIO Fortress Biotech	$2.85 -2.1%	$3.07	$1.99 ▼ $4.53	$97.05M	1.21	749,004 shs	531,158 shs
RFL Rafael	$1.83 -1.6%	$2.36	$1.12 ▼ $3.96	$96.72M	0.33	94,405 shs	149,827 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+1.94%	+3.95%	-7.06%	-0.63%	-71.79%
CLRB Cellectar Biosciences	+2.66%	+2.27%	+5.52%	-16.12%	-40.91%
FBIO Fortress Biotech	-2.06%	+3.64%	-14.41%	+2.52%	+30.14%
RFL Rafael	-2.45%	-8.04%	-17.90%	+38.11%	+23.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.58 +1.9%	$1.80	$1.07 ▼ $6.18	$93.51M	1.21	897,182 shs	982,193 shs
CLRB Cellectar Biosciences	$2.66 +2.7%	$2.58	$2.20 ▼ $6.52	$24.48M	0.55	40,838 shs	56,234 shs
FBIO Fortress Biotech	$2.85 -2.1%	$3.07	$1.99 ▼ $4.53	$97.05M	1.21	749,004 shs	531,158 shs
RFL Rafael	$1.83 -1.6%	$2.36	$1.12 ▼ $3.96	$96.72M	0.33	94,405 shs	149,827 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+1.94%	+3.95%	-7.06%	-0.63%	-71.79%
CLRB Cellectar Biosciences	+2.66%	+2.27%	+5.52%	-16.12%	-40.91%
FBIO Fortress Biotech	-2.06%	+3.64%	-14.41%	+2.52%	+30.14%
RFL Rafael	-2.45%	-8.04%	-17.90%	+38.11%	+23.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	248.10% Upside
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	313.69% Upside
FBIO Fortress Biotech	2.25	Hold	$17.00	496.49% Upside
RFL Rafael	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLRB, RFL, FBIO, and ALDX Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/17/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/14/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/17/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/12/2026	CLRB Cellectar Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
5/28/2026	RFL Rafael	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/20/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.63 per share	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$3.16 per share	N/A
FBIO Fortress Biotech	$68.47M	1.39	N/A	N/A	$6.18 per share	0.46
RFL Rafael	$920K	103.43	N/A	N/A	$1.91 per share	0.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	11/4/2026 (Estimated)
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
FBIO Fortress Biotech	$6.82M	$2.64	1.08	N/A	N/A	163.32%	83.47%	42.98%	N/A
RFL Rafael	-$30.52M	-$0.68	N/A	N/A	N/A	-3,321.74%	-41.27%	-35.32%	10/28/2026 (Estimated)

Latest CLRB, RFL, FBIO, and ALDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
RFL Rafael	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
CLRB Cellectar Biosciences	N/A	6.66	6.66
FBIO Fortress Biotech	0.17	3.96	3.83
RFL Rafael	N/A	3.16	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
CLRB Cellectar Biosciences	16.41%
FBIO Fortress Biotech	96.51%
RFL Rafael	11.30%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
CLRB Cellectar Biosciences	2.58%
FBIO Fortress Biotech	28.50%
RFL Rafael	32.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	60.33 million	53.21 million	Optionable
CLRB Cellectar Biosciences	10	9.45 million	9.21 million	No Data
FBIO Fortress Biotech	170	33.35 million	23.85 million	Optionable
RFL Rafael	20	52.00 million	34.89 million	Optionable

CLRB, RFL, FBIO, and ALDX Headlines

Recent News About These Companies

Short Interest in Rafael Holdings, Inc. (NYSE:RFL) Rises By 89.0%

July 30, 2026 | marketbeat.com

Rafael Holdings Inc Share Price (RFL.US)

July 15, 2026 | lse.co.uk

Rafael Holdings Insider Trading Activity | NYSE:RFL | Benzinga

July 2, 2026 | benzinga.com

Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

June 29, 2026 | seekingalpha.com

Rafael Holdings (NYSE:RFL) Stock, Short Interest Report

June 25, 2026 | benzinga.com

Rafael Holdings (NYSE: RFL) - Share Price and Research

June 25, 2026 | intelligentinvestor.com.auI

Rafael B Stock Price History

June 11, 2026 | investing.com

Rafael Holdings, Inc. Reports Q3 Fiscal 2026 Financial Results and Progress on Phase 3 TransportNPC™ Trial

June 11, 2026 | quiverquant.comQ

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

June 11, 2026 | globenewswire.com

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick ...

June 10, 2026 | finance.yahoo.com

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

June 10, 2026 | globenewswire.com

Rafael Holdings Insider Ups Holding By 1,810% During Year

April 28, 2026 | finance.yahoo.com

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve ...

April 22, 2026 | caledonianrecord.comC

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

April 22, 2026 | markets.businessinsider.com

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

April 22, 2026 | globenewswire.com

Rafael Holdings Inc. Wt

April 4, 2026 | barrons.com

Rafael Holdings, Inc.: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

March 17, 2026 | finanznachrichten.de

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

March 16, 2026 | globenewswire.com

Rafael Holdings (NYSE:RFL) Short Interest Falls on NYSE Composite

March 1, 2026 | kalkinemedia.comK

Rafael Deepens Space Focus As IPO Decision Looms

February 4, 2026 | aviationweek.comA

Rafael: Crisis hurts play, but players still to blame for poor form | OneFootball

January 26, 2026 | onefootball.comO

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, RFL, FBIO, and ALDX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$1.58 +0.03 (+1.94%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$1.57 -0.01 (-0.38%)

As of 04:01 AM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Cellectar Biosciences NASDAQ:CLRB

$2.66 +0.07 (+2.66%)

Closing price 08/19/2026 03:58 PM Eastern

Extended Trading

$2.64 -0.02 (-0.90%)

As of 04:20 AM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Fortress Biotech NASDAQ:FBIO

$2.85 -0.06 (-2.06%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$2.84 -0.01 (-0.35%)

As of 04:30 AM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Rafael NYSE:RFL

$1.83 -0.03 (-1.61%)

Closing price 08/19/2026 03:59 PM Eastern

Extended Trading

$1.81 -0.02 (-1.09%)

As of 08/19/2026 05:40 PM Eastern

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLRB, RFL, FBIO, and ALDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLRB, RFL, FBIO, and ALDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLRB, RFL, FBIO, and ALDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, RFL, FBIO, and ALDX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Cellectar Biosciences NASDAQ:CLRB

Fortress Biotech NASDAQ:FBIO

Rafael NYSE:RFL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLRB, RFL, FBIO, and ALDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLRB, RFL, FBIO, and ALDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLRB, RFL, FBIO, and ALDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, RFL, FBIO, and ALDX Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Cellectar Biosciences NASDAQ:CLRB

Fortress Biotech NASDAQ:FBIO

Rafael NYSE:RFL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools